Now, they have real-world evidence that patients with 2 common cancers—metastatic breast cancer and metastatic non–small cell ...
For Diana Verrilli, MS, senior vice president and general manager of Navista, the Community Oncology Alliance’s newly ...
Dose-dense adjuvant chemotherapy in patients with HER2-low early breast cancer: An exploratory analysis of the GIM2 trial. Cost consequence model of the MammaPrint (70-gene signature) and 21-gene ...
Median overall survival exceeded SEER benchmarks by 2 months in metastatic NSCLC and 8 months in de novo metastatic breast ...